Mazdutide
IBI362 · LY3305677
PHASE 3 (CHINA) · GLP-1/GLUCAGON DUAL AGONIST
▓ 126 indexed citations across PubMed (48), ClinicalTrials.gov (45), EuropePMC (33).
Citation breakdown by evidence tier
← weaker evidence · stronger evidence →
Tap any tier to jump to that section of the bibliography.
Background
Mazdutide is a dual agonist of the GLP-1 receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM). The drug is developed by Eli Lilly and Innovent Biologics. and is currently in multiple Phase III studies. In May 2025, a result of Phase III study has shown that once-weekly mazdutide led to clinically relevant reductions in body weight in Chinese adults with overweight or obesity.
Mechanism of action
Oxyntomodulin analog; activates GLP-1 and glucagon receptors
Researched effects
Weight loss; glycemic control; hepatic fat reduction (Phase 2/3 China)
Reported efficacy (trial readout)
-
Weight Loss 14%
NEJM (Phase 3, 48wk, n=203)
High confidencen=203Phase 32025 -
Hba1c Reduction 2.2%
Nature (Phase 3, 24wk, n=107)
High confidencen=107Phase 32026 -
Waist Circumference Reduction 17%
Diabetes Obes Metab (Phase 1, 20wk, n=12)
Medium confidencen=12Phase 12025
Trial-efficacy data current as of November 16, 2026.
Live evidence
Active clinical trials 26
- Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 Diabetes
- ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
- QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
- Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
- A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Live signals refreshed daily. Current as of November 19, 2026.
Dosing reported in literature
3-9 mg SC weekly
Known concerns
GI effects; no Western approval
Top-ranked picks
10 pre-curated authoritative sources, ranked by journal tier and study weight.
- Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
- Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.
- Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
- GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.
- Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
- Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
- SUN-654 Comparative Efficacy and Safety of Glucagon Receptor Agonists in Metabolic Outcomes: A Network Meta-Analysis of Randomized Controlled Trials
- Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
- Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.
Full citation library
Year distribution
No references match — clear filters.
Meta-Analyses
13-
1.
This study aimed to provide evidence-based support and a reference for the efficacy and safety of seven glucagon-like peptide-1 (GLP-1) receptor agonists and polyagonists for weight loss in patients with obesity or overweight through a network meta-analysis. Relevant randomized controlled trials (RCTs) with an intervention duration of at least 16 weeks assessing seven GLP-1 receptor agonists and polyagonists (mazdutide, 6 or 4.5 mg; retatrutide, 12 or 8 mg; tirzepatide, 15 or 10 mg; liraglutide,…
-
2.
The rapid development of multi-receptor drugs targeting glucagon-like peptide-1 receptor (GLP-1R) is driving significant advancements in the treatment of individuals with type 2 diabetes and obesity. This systematic review and network meta-analysis aims to compare the efficacy and safety of multi-receptor drugs in adults with overweight or obesity, with or without type 2 diabetes. A systematic search was conducted in PubMed, Cochrane, Web of Science, Embase, CNKI, and WanFang databases up to May…
-
3.
Overweight and obesity are increasing global public health problems. Mazdutide is a new dual agonist drug that can potentially reduce weight and blood glucose levels simultaneously. However, the synthesis of evidence on the efficacy and safety of this drug is scarce. Therefore, this study aimed to synthesize evidence on the efficacy and safety of Mazdutide compared to placebo on weight reduction among adults with and without diabetes. We conducted a systematic review and meta-analysis of randomi…
- 4.
-
5.
This study aimed to investigate the effects of randomized, placebo-controlled trials involving the GLP-1 and glucagon receptor dual agonists, mazdutide, and cotadutide, on glycaemic control and body weight changes in individuals with type 2 diabetes mellitus (T2DM), obesity, or both. We conducted searches in Medline, PubMed, Scopus, the Cochrane database, and Web of Science up to March 5, 2024. The primary outcomes assessed were changes in HbA1c level and percentage changes in body weight from b…
-
6.
Glucagon receptor agonists (GRAs) are an emerging class of therapies for obesity and type 2 diabetes, demonstrating encouraging metabolic and weight-reducing effects. Several investigational GRA-based agents, including retatrutide, cotadutide, mazdutide, and survodutide, have reported promising results across early and mid-phase clinical trials. This comprehensive meta-analysis evaluates the efficacy and safety of these agents in individuals with type 2 diabetes, overweight, or obesity. PubMed,…
-
7.
Mazdutide, a dual GLP-1 and glucagon receptor agonist, shows promise for weight loss and glycaemic control. This study evaluates its efficacy in non-diabetic patients with obesity. A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity. Meta-analysis was performed using RevMan 5.4 with random-effect models. Five RCTs were included. Mazdutide significantly reduced percentage body w…
-
8.
Incretin-based dual and triple agonists have emerged as effective options for obesity management, offering enhanced weight loss through multi-receptor agonism. However, data on their efficacy and safety remain limited. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of these emerging agents. A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled tri…
-
9.
<h4>Background</h4>Obesity is a complex condition marked by excessive body fat, linked to comorbidities such as type 2 diabetes and cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for diabetes, are increasingly used for weight management.<h4>Methods</h4>We conducted a systematic review and meta-analysis of randomized controlled trials (PubMed, last 5 years, English language) evaluating GLP-1-based pharmacotherapies versus placebo or active comparato…
- 10.
-
11.
Dual glucagon-like peptide-1/glucagon receptor (GLP-1/GCGR) agonists represent a novel obesity treatment class, but existing meta-analyses often conflate them with GIP-containing agents (tirzepatide, retatrutide) or restrict analysis to one or two drugs, leaving class-specific efficacy and safety incompletely characterized. We systematically searched PubMed, Embase, Cochrane Library, Scopus and ClinicalTrials.gov through 20 July 2026 for randomized controlled trials of mazdutide, survodutide, co…
-
12.
To assess the effects of mazdutide on body weight, HbA1c, metabolic outcomes, and adverse events in adults with overweight/obesity and/or type 2 diabetes (T2D). This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026. Co-primary outcomes were percent change in body weight an…
-
13.
Type 2 diabetes mellitus (T2DM) is closely linked to obesity and carries a high risk of metabolic complications. While GLP-1 receptor agonists like dulaglutide improve blood sugar and support modest weight loss, many patients do not reach their treatment goals. Mazdutide, a dual GLP-1 and glucagon receptor agonist, may offer stronger metabolic benefits. To compare the efficacy and safety of mazdutide versus dulaglutide in adults with T2DM. We systematically reviewed randomized controlled trials…
Systematic Reviews
1-
14.
The history of antiobesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the prevailing conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or US Food…
Randomised Controlled Trials
10-
15.
Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in persons with overweight or obesity. In a phase 3, double-blind, placebo-controlled trial in China, we randomly assigned, in a 1:1:1 ratio, adults 18 to 75 years of age who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 28 or had a BMI of 2…
-
16.
We conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of mazdutide, a once-weekly glucagon-like peptide 1 and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes. Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg ma…
-
17.
Mazdutide is a once-weekly glucagon and glucagon-like peptide 1 receptor dual agonist developed for the treatment of type 2 diabetes (T2D)
-
18.
Mazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. We evaluated the efficacy and safety of 24-week treatment of mazdutide up to 6 mg in Chinese overweight adults or adults with obesity, as an interim analysis of a randomised, two-part (low doses up to 6 mg and high dose of 9 mg), double-blind, placebo-controlled phase 2 trial (ClinicalTrials.gov, NCT04904913). Overweight adults (body-mass index [BMI] ≥24 kg/m
-
19.
Despite advances in type 2 diabetes (T2D) management, unmet needs remain for therapies that effectively control hyperglycaemia while addressing comorbid metabolic disorders
-
20.
The success of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes (T2D) and obesity has sparked considerable efforts to develop next-generation co-agonists that are more effective. We conducted a randomised, placebo-controlled phase 1b study (ClinicalTrials.gov: NCT04466904) to evaluate the safety and efficacy of IBI362 (LY3305677), a GLP-1 and glucagon receptor dual agonist, in Chinese patients with T2D. A total of 43 patients with T2D were enrolled in three cohorts in n…
-
21.
Mazdutide, an agonist of glucagon-like peptide-1 and glucagon receptors, significantly reduced weight in early phase trials at doses up to 10 mg. This randomized, double-blind, placebo-controlled Phase 1 trial evaluated the safety and efficacy of mazdutide up to 16 mg in adults with overweight or obesity. Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous injections of mazdutide (n = 24) or placebo (n = 8) for 20 weeks. Two mazdutide dose escalation regi…
-
22.
Once-weekly dual glucagon and glucagon-like peptide-1 receptor agonist mazdutide, administered at 4 and 6 mg, provides substantial weight loss in Chinese adults with overweight or obesity. This trial aimed to evaluate the efficacy and safety of mazdutide 9 mg in Chinese adults with obesity. In this randomized, double-blind, placebo-controlled phase 2 trial (NCT01904913), participants with a body mass index (BMI) ≥30 kg/m Eighty participants were randomized and received mazdutide 9 mg (n = 60) or…
-
23.
Therapies targeting GLP-1 or glucose-dependent insulinotropic polypeptide (GIP) receptors have provided efficacious weight reduction in adults with obesity. Mazdutide, a glucagon and GLP-1 receptor dual agonist, presents a novel opportunity for differentiated weight reduction. We aimed to evaluate the efficacy, safety, and tolerability of once-weekly mazdutide across a dose range up to 16 mg in adults with obesity or overweight without type 2 diabetes in the USA. In this randomised, double-blind…
-
24.
Obesity is a worldwide problem and a major public health issue in China. To evaluate the efficacy and safety of mazdutide (a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist) in Chinese adults with obesity (defined as a body mass index of ≥30). A double-blind, placebo-controlled, phase 3, randomized clinical trial including Chinese adults with or without type 2 diabetes that was conducted at 27 hospitals from December 2023 to November 2025. Participants were randomized in a…
Clinical Trials
1-
25.
Effective weight management and glycemic control are both important in people with type 2 diabetes (T2D) and obesity. Despite the proven benefits of GLP-1 receptor agonists, there is a persistent need for more effective weight management strategies in the treatment of T2D and obesity. Glucagon receptor-based co-agonists, such as mazdutide, represent a promising therapeutic class with the potential for enhanced weight loss compared to current standards of care. However, robust clinical evidence f…
Trial Registrations (ClinicalTrials.gov)
45-
26.
Conditions: Healthy
-
27.
Conditions: Obesity Or Overweight
-
28.
Conditions: Overweight or Obesity
-
29.
Conditions: Type 2 Diabetes
-
30.
Conditions: Severe Obesity
-
31.
Conditions: Alcohol Use Disorder
-
32.
Conditions: Overweight, Obesity
-
33.
Conditions: Healthy
-
34.
Conditions: Type 2 Diabetes
- 35.
-
36.
Conditions: Sleep Apnea, Obstructive, Obesity
-
37.
Conditions: Overweight, Obesity, Hypertensive
-
38.
Conditions: Type 2 Diabetes, Obesity
-
39.
Conditions: Overweight Subjects, Obese Subjects
-
40.
Conditions: Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
-
41.
Conditions: Obesity
-
42.
Conditions: Overweight/ Obesity
-
43.
Conditions: Obesity, Overweight and Obesity
-
44.
Conditions: Obesity, Weight Control
-
45.
Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction
-
46.
Conditions: Type 2 Diabetes
-
47.
Conditions: Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
-
48.
Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH)
-
49.
Conditions: Adolescents With Obesity
-
50.
Conditions: Adolescents With Obesity or Overweight With Weight-Related Comorbidities
- 51.
-
52.
Conditions: Type 2 Diabetes
- 53.
-
54.
Conditions: Polycystic Ovary Syndrome
-
55.
Conditions: Diabetes Mellitus, Type 2
-
56.
Conditions: Renal Impairment
-
57.
Conditions: Obesity
-
58.
Conditions: Type 1 Diabetes
-
59.
Conditions: Cirrhosis, Portal Hypertension, Fatty Liver Disease (+1)
-
60.
Conditions: Obesity & Overweight, Coronary Heart Disease
-
61.
Conditions: Gout, Obesity (BMI>30), Hyperuricemia (+1)
-
62.
Conditions: Type 2 Diabetic Kidney Disease
-
63.
Conditions: Type 2 Diabetes
-
64.
Conditions: Prediabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance (Prediabetes)
-
65.
Conditions: Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
-
66.
Conditions: Diabetes Mellitus, Type 2
-
67.
Conditions: Obesity, Overweight, Atypical Endometrial Hyperplasia (+2)
-
68.
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
Conditions: Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis, Living Liver Donors
-
69.
Conditions: Atrial Fibrillation (AF), Ablation Treatment, Obesity & Overweight (+1)
-
70.
Conditions: Fatty Pancreas, Overweight, Obesity
Reviews
12-
71.
Mazdutide (Xinermei
-
72.
Recent studies with peptide-based incretin therapies have focussed mainly on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and the dual agonist tirzepatide that engages receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). Randomised clinical trials and 'real-world' studies have confirmed the marked glucose-lowering and weight-lowering efficacy of these agents across diverse populations. These include different ethnic groups, young and elderly individuals…
-
73.
The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success, novel glucagon-like peptide-1 (GLP-1)-based therapeutics are rapidly advancing. These next-generation agents engage not only GLP-1 receptors but also those for other gastro-entero-pancreatic hormones such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, amylin, and peptide YY to enhance energy uptake, storage, and expenditure through syn…
-
74.
The prevalence of overweight and obesity in China has continued to increase over the last decade, with mounting health and economic consequences. In this Personal View, we critically examine recent advances and identify current and emerging challenges in obesity across public health and policy, clinical research, and practice. National policy frameworks, technical health and nutrition guidelines, and multisectoral collaboration have elevated obesity on the public agenda. Evidence supporting life…
-
75.
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have changed the landscape of type 2 diabetes (T2D) management due to their cardio-renal benefits, their glucose-lowering efficacy and weight loss (WL) maintenance. However, the response to GLP-1 RA monotherapy is heterogeneous. Additionally, the majority of GLP-1 RAs are injectable treatments. Oral GLP-1 RAs and injectable combinations of GLP-1 with other entero-pancreatic hormones (glucose-dependent insulinotropic polypeptide (GIP), gluca…
-
76.
Obesity is a heterogeneous, complex, and chronic disease that has a detrimental impact on disability-adjusted life years across the globe. Recent advancements in our understanding of gut-brain communication at the molecular level have driven the development of next-generation anti-obesity medications (AOMs). Glucagon-like peptide-1 receptor agonists (GLP1RAs) remain the front-runners in this rapidly evolving landscape of hormone-based AOMs. Two GLP1RAs, namely Liraglutide and Semaglutide, have b…
-
77.
Mazdutide is a dual glucagon-like peptide-1 receptor (GLP-1 R) and glucagon receptor (GCGR) agonist representing a new generation of incretin-based therapeutics for obesity and type 2 diabetes. While its clinical efficacy is increasingly recognized, the intellectual property framework that underpins its development and long-term positioning has not been systematically examined. This review presents a comprehensive patent landscape analysis of mazdutide and related oxyntomodulin analogs. Patent d…
-
78.
The global rise in obesity and its associated health risks has driven the need for more effective pharmacological treatments. Glucagon receptor (GCGR)-based multi-agonist drugs are emerging as promising treatments for obesity, with several in advanced stages of clinical development. Agents like mazdutide, pemvidutide, survodutide and retatrutide have demonstrated the ability to trigger significant weight loss in earlier phase trials, often surpassing the amount of weight loss obtained with exist…
-
79.
Glucagon is a pancreatic peptide hormone whose receptor (GCGR) is expressed in the liver, kidney, and, to a lesser extent, various other tissues. Glucagon is well known as the counterpart to insulin in glucose homeostasis. However, recent evidence has revealed other potential roles of glucagon, which include the regulation of amino acid metabolism via a liver-pancreatic alpha cell axis, stimulation of lipolysis and mitochondrial fat oxidation in the liver (and possibly in other tissues), reducti…
-
80.
The epidemics of metabolic disease, in the form of obesity and type 2 diabetes, are a growing public health concern. However, incretin-based therapeutics have transformed our ability to address these diseases. While this current generation of incretin analogues show weight regain upon cessation of treatment, the amount of which can depend on the treatment and patient, iterative advancements may improve weight loss durability in the long term. In this review, we discuss the development of glucago…
-
81.
Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss previously considered attainable only with bariatric surgery. However, GLP-1-based therapies have revealed important limitations, including weight loss plateaus, substantial inter-individual variability, and weight regain upon discontinuation, underscori…
-
82.
Cardio-kidney-metabolic diseases including obesity, metabolic dysfunction-associated liver disease, and type 2 diabetes have reached pandemic prevalence, fueling the search for new treatments for these conditions, given their associated complications, notably cardiovascular disease. Dual agonists of the glucagon and glucagon-like peptide (GLP-1) receptors are promising. Certain GLP-1 receptor monoagonists are indicated for treatment of type 2 diabetes, obesity, and metabolic dysfunction-associat…
Research Articles
36-
83.
Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week body weight loss up to 6.4% at doses up to 6 mg in Chinese adults with overweight or obesity. We further explored the safety and efficacy of mazdutide dosed up to 9 mg and 10 mg. In this randomised, placebo-controlled, multiple-ascending-dose phase 1b trial, we enrolled adults (aged 18-75 years, both inclusive) with overweight (body-mass index [B…
-
84.
IBI362 (LY3305677) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes. The aim of this randomised, placebo-controlled, multiple ascending dose phase 1b study was to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI362 in Chinese adults with overweight or obesity. This study enrolled adults with overweight (body mass index [BMI]≥24 kg/m Between June 15 IBI362 was well tolerated an…
-
85.
Cognitive impairment and dementia are highly associated with obesity and type 2 diabetes mellitus (T2DM). Recent studies have demonstrated that GLP-1 receptor agonists can improve cognitive function through brain activation in patients with T2DM, compared to other oral glucose-lowering drugs. Mazdutide, a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), has been shown to simultaneously reduce body weight, blood glucose levels, and other comorbiditie…
- 86.
- 87.
-
88.
Background Glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, along with GLP-1R monoagonist, show promise in treating metabolic dysfunction-associated steatotic liver disease (MASLD). Liver fat and iron content are important surrogate markers for disease assessment. However, it remains unclear whether dual agonists provide superior therapeutic benefit over monoagonists for hepatic fat and iron regulation. Purpose To evaluate whether a GLP-1R/GCGR dual agonist of…
- 89.
-
90.
To conduct a systematic, multi-dimensional clinical evaluation of five long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) available in China, providing evidence-based guidance for clinical preference and institutional formulary selection. This study was structured according to the "A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions. (Second Edition)" and the "Guidelines for the Workflow of Clinical Comprehensive Evaluation of Drugs" We constructed a…
-
91.
Glucagon-like-peptide-1 receptor (GLP-1R) agonists are under development as new drugs to treat type 2 diabetes, liver disease, obesity and cardiovascular diseases. Some of these drugs are solely agonists of the GLP-1R. It turned out that their benefit could be improved when they also stimulated the glucagon receptor (GCGR) and/or the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR). Stimulation of GLP-1R in cell cultures but also in neonatal atrial and/or ventricular cardiomyoc…
-
92.
Obesity requires treatment as it is associated with health problems such as type 2 diabetes, hypertension, dyslipidemia, cardiovascular diseases, and some cancers, which increase mortality rates. Achieving sufficient weight loss to reduce obesity-related diseases requires a variety of interventions, including comprehensive lifestyle modification of diet and exercise, change in behavior, anti-obesity medications, and surgery. To date, anti-obesity agents with various mechanisms of action have bee…
-
93.
Incretins are gut hormones involved in maintaining metabolic homeostasis in the human body, and disorders of the incretin system are recognized as contributing to the pathobiology of metabolic dysfunction and obesity. Incretin polyagonists are transforming the landscape of obesity treatment by offering potent, non-surgical alternatives to bariatric procedures. Acting on multiple incretin and related receptors, these novel pharmacological agents harness the synergistic effects of gut hormones suc…
-
94.
Abstract <h4>Background</h4> IBI362, a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week weight loss up to 6.4% at doses up to 6 mg in Chinese participants with overweight or obesity. We further explored the safety and efficacy of IBI362 dosed up to 9 mg and 10 mg. <h4>Methods</h4> Two high-dose cohorts from a randomized, placebo-controlled, multiple ascending dose study (NCT04440345) enrolled adults with overweight (body mass index [BMI] ≥24…
-
95.
Metabolic dysfunction-associated steatotic liver disease (MASLD), a progressive liver disease frequently associated with metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity, has the potential to progress symptomatically to liver cirrhosis and, in some cases, hepatocellular carcinoma. Hence, an urgent need arises to identify and approve new therapeutic options to improve patient outcomes. Research efforts have focused on either developing dedicated molecules or repurposing dru…
-
96.
Obesity poses a significant global health challenge, with an alarming rise in prevalence rates. Traditional interventions, including lifestyle modifications, often fall short of achieving sustainable weight loss, ultimately leading to surgical interventions, which carry a significant burden and side effects. This necessitates the exploration of effective and relatively tolerable pharmacological alternatives. Among emerging therapeutic avenues, glucagon-based treatments have garnered attention fo…
-
97.
Obesity is a chronic, relapsing disease with multifactorial origins and significant global health implications. Historically, bariatric surgery has been the most effective intervention for achieving sustained weight loss and metabolic improvement, especially in individuals with moderate to severe obesity. However, the therapeutic landscape is rapidly evolving. Recent advances in pharmacotherapy-including GLP-1 receptor agonists, dual and triple incretin agonists, and amylin-based combination the…
-
98.
<h4>Objectives</h4>To identify and summarize studies carried out in Arab countries on anti-obesity medications (AOMs), with a focus on the types of medications investigated, study designs, and the efficacy/effectiveness and safety metrics reported.<h4>Methods</h4>We carried out a comprehensive scoping review of primary studies examining the use of AOMs in adult Arab populations. Five databases (Medline, Embase, Cochrane Library, Index Medicus for the Eastern Mediterranean Region, and e-Marefa) w…
-
99.
<b>Objective:</b> Diabetes mellitus encompasses chronic metabolic disorders marked by impaired insulin secretion, action, or both, with type 1 and type 2 diabetes presenting distinct mechanisms and therapeutic needs. Achieving durable glycemic control remains essential to preventing microvascular and macrovascular complications. <b>Data Sources:</b> The growing prevalence of obesity among people with diabetes-driven by insulin resistance, lifestyle factors, and, in type 1 diabetes, insulin-assoc…
-
100.
The ground-breaking development of the incretin agonists by manipulation of the incretin system, including the gut hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), as well as the pancreatic hormone glucagon, has led to the emergence of promising pharmacotherapy for metabolic health. The GLP-1 receptor agonists (GLP-1RAs), namely liraglutide, dulaglutide, albiglutide, exenatide, and semaglutide, have been found to have beneficial effects on glycated…
-
101.
Glucagon-like peptide-1 (GLP-1) is an incretin peptide hormone mainly secreted by enteroendocrine intestinal L-cells. GLP-1 is also secreted by α-cells of the pancreas and the central nervous system (CNS). GLP-1 secretion is stimulated by nutrient intake and exerts its effects on glucose homeostasis by stimulating insulin secretion, gastric emptying confiding the food intake, and β-cell proliferation. The insulinotropic effects of GLP-1, and the reduction of its effects in type 2 diabetes mellit…
-
102.
The secretin-like, class B1 subfamily of seven transmembrane-spanning G protein-coupled receptors (GPCRs) consists of 15 members that coordinate important physiological processes. These receptors bind peptide ligands and use a distinct mechanism of activation that is driven by evolutionarily conserved structural features. For the class B1 receptors, the C-terminus of the cognate ligand is initially recognized by the receptor via an N-terminal extracellular domain that forms a hydrophobic ligand-…
-
103.
The objective is to review the newer pharmacological interventions for obesity, specifically single, dual and triple incretin receptor agonists that are either available or in the pipeline for treatment of obesity. The three incretin receptor targets are glucagon like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and glucagon. There are several approved single or dual incretin agonists which can be administered subcutaneously daily (e.g., liraglutide) or weekly (e.g., semaglu…
- 104.
-
105.
<b>Background/Objectives</b>: Obesity has a huge impact on global healthcare and economy. Consequently, the pharmaceutical industry has recently introduced novel anti-obesity drugs such as semaglutide and tirzepatide, which can yield remarkable weight reduction in patients, while also having significant cardiovascular benefits. <b>Methods</b>: Other weight-lowering medications are currently under investigation, and this narrative review provides an overview of the main novel drugs that are being…
-
106.
Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results i…
-
107.
Diabetic foot ulcer (DFU), a severe chronic complication of diabetes mellitus, poses a major public health threat due to its high rates of disability, recurrence, and all-cause mortality. The mortality rate of DFU patients is closely related to cardiovascular events, indicating that their treatment should go beyond local wound management and focus on cardiovascular risk intervention. Glucagon-like peptide-1 receptor agonists (GLP-1 RA), known for their cardiovascular protective effects demonstra…
-
108.
Incretins, such as glucagon-like peptide-1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP), have advanced the treatment landscape of obesity to a new pinnacle. As opposed to singular incretin effects, oxyntomodulin (OXM) activates glucagon receptors (GCGR) and glucagon-like peptide-1 receptors (GLP1R), demonstrating a more dynamic range of effects that are more likely to align with evolving 'health gains' goals in obesity care. Here, we will review the molecular insights from their…
-
109.
The global surge in cardiometabolic diseases, including type 2 diabetes, obesity, and cardiovascular diseases, has reached pandemic levels, demanding bold and innovative solutions. Dual glucagon (Gcg) and glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking advancement in the treatment of this complex and interconnected spectrum of disorders. By harnessing the synergistic power of GLP-1 and Gcg receptor activation, these agents go beyond glucose lowering and weight loss,…
-
110.
The increasing prevalence of obesity and type 2 diabetes (T2DM) is provoking an important socioeconomic burden mainly in the form of cardiovascular disease (CVD). One successful strategy is the so-called metabolic surgery whose beneficial effects are beyond dietary restrictions and weight loss. One key underlying mechanism behind this surgery is the cooperative improved action of the preproglucagon-derived hormones, glucagon, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic…
-
111.
Obesity is closely related to metabolic diseases, which brings a heavy burden to the health care system. It is urgent to formulate and implement effective treatment strategies. Glucagon-like peptide-1 (GLP-1) is a protein with seven transmembrane domains connected by type B and G proteins, which is widely distributed and expressed in many organs and tissues. GLP-1 analogues can reduce weight, lower blood pressure, and improve blood lipids. Obesity, diabetes, cardiovascular diseases, and other di…
-
112.
<h4>Purpose of review</h4>The development of long-acting incretin receptor agonists represents a significant advance in the fight against the concurrent epidemics of type 2 diabetes mellitus (T2DM) and obesity. The aim of the present review is to examine the cellular processes underlying the actions of these new, highly significant classes of peptide receptor agonists. We further explore the potential actions of multi-agonist drugs as well as the mechanisms through which gut-brain communication…
-
113.
Pharmacological management of obesity long suffered from a reputation of a 'Mission Impossible,' with inefficient weight loss and/or unacceptable tolerability. However, the tide has turned with recent progress in biochemical engineering and the development of long-acting agonists at the receptor for glucagon-like peptide-1 (GLP-1), and with unimolecular peptides that simultaneously possess activity at the receptors for GLP-1, the glucose-dependent insulinotropic polypeptide (GIP) and glucagon. S…
-
114.
Within recent decades glucagon receptor (GcgR) agonism has drawn attention as a therapeutic tool for the treatment of type 2 diabetes and obesity. In both mice and humans, glucagon administration enhances energy expenditure and suppresses food intake suggesting a promising metabolic utility. Therefore synthetic optimization of glucagon-based pharmacology to further resolve the physiological and cellular underpinnings mediating these effects has advanced. Chemical modifications to the glucagon se…
-
115.
Obesity is a multifaceted disease that poses a significant public health challenge. Recent discoveries in understanding the biological pathways that regulate satiety and metabolism have led to a shift in the treatment paradigm for obesity. Thus, the gap between pharmacological and surgical interventions has diminished. The latest approved antiobesity medications help to achieve weight loss comparable to surgery. These GLP-1 analog-based therapies not only cause substantial weight loss but also i…
- 116.
- 117.
- 118.
Preprints (not yet peer-reviewed)
6-
119.
<h4>Background: </h4> Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder globally. Mazdutide has shown clinical benefits in weight management and metabolic regulation, indicating its potential as a therapeutic agent for NAFLD. This study aimed to investigate the efficacy and mechanism of action of Mazdutide against early-stage NAFLD. <h4>Methods:</h4> A NAFLD mouse model was induced by a 12-week high-fat diet, followed by a 4-week treatment with subcutaneous M…
-
120.
<title>Abstract</title> <p>Purpose Mazdutide is a dual GLP-1 and glucagon receptor agonist under investigation for weight management in obesity. This meta-analysis evaluated its efficacy in nondiabetic adults with overweight or obesity. Methods We searched PubMed, Scopus, and Web of Science for randomized controlled trials (RCTs) comparing mazdutide with placebo. Primary outcomes included changes in body weight, BMI, and waist circumference. A random-effects model was used. Results Four RCTs (n…
-
121.
<title>Abstract</title> <p> <bold>Background:</bold> Diabetes mellitus remains a leading global health challenge, with 589 million adults affected in 2024 and projections exceeding 850 million by 2050 (IDF, 2025). The year 2025 marked a watershed in diabetes therapeutics, with regulatory approvals advancing beyond glycemic control to integrated cardio–renal–metabolic protection. <bold>Objectives:</bold> To systematically evaluate antidiabetic drug approvals in 2025, synthesize emerging clinical…
-
122.
<h4>Background: </h4> Type 2 diabetes mellitus (T2DM) remains a major global health burden. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as dulaglutide improve glycemic control and promote weight loss, many patients do not achieve optimal metabolic targets. Mazdutide, a dual GLP-1 and glucagon receptor agonist, may provide greater efficacy. This systematic review and meta-analysis compared the efficacy and safety of mazdutide versus dulaglutide in adults with T2DM. Methods…
-
123.
<h4>Background: </h4> Mazdutide, a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist, has shown promising metabolic benefits in randomized controlled trials (RCTs) of adults with type 2 diabetes mellitus (T2DM). However, its efficacy and safety have not been systematically synthesized. Objective To evaluate the efficacy and safety of mazdutide versus placebo in adults with T2DM. Methods A systematic review and meta-analysis of RCTs was conducted according to PRISMA 2020 guidelin…
-
124.
<title>Abstract</title> <p> <bold>Background</bold> : Mazdutide, a dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonist, has emerged as a promising therapy for obesity and overweight. However, its comparative dose-dependent efficacy and safety across multiple cardiometabolic outcomes remain to be comprehensively evaluated. Therefore, a Bayesian network meta-analysis was conducted to assess the effects of different Mazdutide doses in adults with obesity or overweigh…
Case Reports
2-
125.
Mazdutide, a glucagon-like peptide-1/glucagon receptor (GLP - 1/GCGR) dual agonist, has shown marked efficacy in glycemic control, weight loss, and metabolic improvement in adults. However, data in adolescents remain limited. This report explores its therapeutic potential in an adolescent with obesity-related type 2 diabetes mellitus (T2DM) and hyperuricemia (HUA). We report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg/m²), type 2 diabetes mellitus (HbA1c: 9.60%),…
- 126.
Curated sources on file
23- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.